Early Clinical Response as a Predictor of Late Treatment Success in Patients With Acute Bacterial Skin and Skin Structure Infections: Retrospective Analysis of 2 Randomized Controlled Trials

Clin Infect Dis. 2017 Jan 15;64(2):214-217. doi: 10.1093/cid/ciw750. Epub 2016 Dec 21.

Abstract

In the treatment of acute bacterial skin and skin structure infections, pooled data from 2 clinical trials (N = 1333 patients) showed that programmatic and investigator-assessed early treatment success both had a high positive predictive value (94.3%-100.0%) for late clinical cure, including among hospitalized patients. The negative predictive value of programmatic early success was <20%. These exploratory findings require prospective real-world evaluation.

Clinical trials registration: NCT01170221; NCT01421511.

Keywords: ABSSSI; antibacterial therapy; oxazolidinones; tedizolid; treatment outcomes..

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Clinical Trials, Phase III as Topic
  • Humans
  • Linezolid / therapeutic use
  • Models, Statistical
  • Organophosphates / therapeutic use
  • Oxazoles / therapeutic use
  • Randomized Controlled Trials as Topic
  • Retrospective Studies
  • Sensitivity and Specificity
  • Skin Diseases, Bacterial / drug therapy*
  • Skin Diseases, Bacterial / microbiology
  • Time Factors
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Organophosphates
  • Oxazoles
  • Linezolid
  • tedizolid phosphate

Associated data

  • ClinicalTrials.gov/NCT01170221
  • ClinicalTrials.gov/NCT01421511